---
schema_version: "secwatch.filing_event.v1"
accession: "0001619856-24-000003"
form_type: "8-K"
ticker: "CRBU"
cik: "0001619856"
company_name: "Caribou Biosciences, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:19:27.631973+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Caribou appoints Tim Kelly as CTO; plans CB-010 pivotal trial by YE 2024, cash into Q4 2025

## Summary
- Tim Kelly appointed CTO; previously CEO of Oxford Biomedica Solutions, led technical ops at Sarepta, Shire, and Biogen.
- $396.7M cash, cash equivalents, and marketable securities as of Sep 30, 2023; expected runway into Q4 2025.
- CB-010: initial dose expansion data from ANTLER trial and RP2D expected Q2 2024; Phase 3 pivotal in 2L LBCL by YE 2024.
- CB-011: initial dose escalation data from CaMMouflage trial expected by YE 2024.
- CB-012: patient enrollment in AMpLify Phase 1 trial for r/r AML expected to initiate H1 2024.

## SEC filing metadata
- accession: 0001619856-24-000003
- form_type: 8-K
- ticker: CRBU
- cik: 0001619856
- company_name: Caribou Biosciences, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000003/0001619856-24-000003-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1619856/000161985624000003/crbu-20240107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001619856-24-000003
- JSON: https://secwatch.observer/filing/0001619856-24-000003.json
- Plain text: https://secwatch.observer/filing/0001619856-24-000003.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.